APA

Willemze R., Suciu S., Muus P., Halkes C. J. M., Meloni G., Meert L., Karrasch M., Rapion J., Vignetti M., Amadori S., de Witte T. & Marie J. P. (20140623). Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). : Annals of hematology.

Chicago

Willemze R, Suciu S, Muus P, Halkes C J M, Meloni G, Meert L, Karrasch M, Rapion J, Vignetti M, Amadori S, de Witte T and Marie J P. 20140623. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). : Annals of hematology.

Harvard

Willemze R., Suciu S., Muus P., Halkes C. J. M., Meloni G., Meert L., Karrasch M., Rapion J., Vignetti M., Amadori S., de Witte T. and Marie J. P. (20140623). Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). : Annals of hematology.

MLA

Willemze R, Suciu S, Muus P, Halkes C J M, Meloni G, Meert L, Karrasch M, Rapion J, Vignetti M, Amadori S, de Witte T and Marie J P. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). : Annals of hematology. 20140623.